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Abstract 
Background 
The role of long-term alcohol consumption for the risk of developing ulcerative colitis 
(UC) and Crohn’s disease (CD) is unclear. 
Aims 
For the first time, to prospectively assess the role of pre-disease alcohol consumption on 
the risk of developing UC or CD. 
Methods 
Nested within the European Prospective Investigation into Cancer and Nutrition (EPIC-
IBD), incident UC and CD cases and matched controls where included. At recruitment, 
participants completed validated food frequency and lifestyle questionnaires. Alcohol 
consumption was classified as either: non-use, former, light (≤0.5 and 1 drink/week), 
below the recommended limits (BRL) (≤1 and 2 drinks/day), moderate (≤2.5 and 5 
drinks/day), or heavy use (>2.5 and >5 drinks/ day) for women and men, respectively; and 
was expressed as consumption at enrolment and during lifetime. Conditional logistic 
regression was applied adjusting for smoking and education, taking light users as the 
reference. 
Results 
Out of 262,451 participants in 6 countries, 198 UC incident cases/792 controls and 84 CD 
cases/336 controls were included. At enrolment, 8%/27%/32%/23%/11% UC cases and 
7%/29%/40%/19%/5% CD cases were: non-users, light, BRL, moderate and heavy users, 
respectively. The corresponding figures for lifetime non-use, former, light, BRL, moderate 
and heavy use were: 3%/5%/23%/44%/19%/6% and 5%/2%/25%/44%/23%/1% for UC 
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and CD cases, respectively. There were no associations between any categories of alcohol 
consumption and risk of UC or CD in the unadjusted and adjusted odds ratios.  
Conclusion 
There was no evidence of associations between alcohol use and the odds of developing 
either UC or CD.  
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Introduction 
The aetiology of the inflammatory bowel diseases (IBD), namely Crohn’s disease 
(CD) and ulcerative colitis (UC), is largely unknown, but may involve a dysfunctional 
immune response to the gut microbiota in those with a genetic susceptibility1. The 
contribution of genetic risk loci in association with IBD was estimated at less than 25 
percent2, leading to the assumption that environmental factors play an important role in 
aetiology. Among investigated environmental factors showing associations so far are: 
dietary intakes of fatty acids, protein, meat, sugars, fibre and fruits, physical activity and 
cigarette smoking3-5. Alcohol consumption is a ubiquitous lifestyle factor in European 
societies closely related to these and other dietary and life style factors6, 7. Hypothetically 
alcohol consumption may be related to IBD via several biological paths. For instance, the 
consumption of alcoholic beverages could have opposing effects on the gut mucosa, as 
ethanol can cause intestinal mucosal injury and increase bacterial translocation8. 
Alternatively, some components of alcoholic beverages such isoflavones could potentially 
have antioxidant and probiotical proprieties and possibly modulate the intestinal 
inflammatory bowel response9. In patients with established IBD10-13, clinical studies have 
reported that alcohol consumption provoked symptoms or increased biomarkers of 
relapse in inactive disease14, and this could explain why patients with IBD avoid its use15 
and why alcohol-related causes of death are less frequent in IBD patients16, 17  
Only a few case-control studies have investigated alcohol consumption, often in 
combination with smoking and diet, in the aetiology of IBD and have reported 
inconsistent results. For UC, no associations were documented in Chinese and Swedish 
populations 18, 19, but there was an inverse association in alcohol users compared to non-
users or infrequent users, in US American and Japanese populations20-23. Epidemiological 
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studies investigating alcohol consumption and the development of CD are scarce; one 
showing consuming alcohol at least once per week lowered the risk24 and another 
reporting no association for use of alcoholic beverages25.  
Limitations of all these retrospective studies, where that they relied on self-reports 
of recalled previous alcohol use, which in cases may have been after establishment of the 
IBD diagnosis rather than before the onset of symptoms ,hence introducing recall bias. In 
prospective cohort studies, where initially healthy people report their diet and alcohol 
consumption and are then followed up to identify those who develop IBD, recall and 
selection biases are reduced. To date, no prospective epidemiological study has 
investigated the lifetime use of alcohol on the development of UC or CD. We aimed to 
address this by assessing whether there is an association between alcohol consumption at 
several time points during a participant’s lifetime prior to the recruitment into the multi-
centre European Prospective Investigation into Cancer and Nutrition (EPIC-IBD) study and 
the subsequent development of UC or CD. 
 
Methods 
The EPIC study recruited approximately 520 000 participants during the years 1992 
until 2000 namely women and men mainly ages 35 to 65 and 40 to 65 years in 23 
collaborating centres in 10 European countries to investigate the role of diet and other 
lifestyle factors in the aetiology of cancer and other chronic diseases in a general 
population with a prospective study design26. At recruitment, participants completed 
questionnaires on diet and lifestyle factors, medical history and underwent 
anthropometric examinations in each centre. The study was approved in each centre by 
the relevant local ethics committee and each participant gave written consent.  
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The EPIC-IBD study was embedded in a sub-cohort of EPIC involving 401,326 initially 
healthy women and men without UC or CD, in the age range 20 to 80 years, recruited 
from 12 centres in 8 European countries. Information on lifetime use of alcohol was not 
collected in all these centres hence the study population was 262,451 participants in 7 
centres in 6 European countries (table 1). The sub-cohorts were followed up until at least 
May 2004 and in some centres until December 2010 where incident cases of UC and CD 
were identified by several methods including national and regional IBD registries, follow-
up questionnaires and hospital databases (table 1). All the medical records of potential 
cases were reviewed to obtain information from radiological, endoscopic, and histological 
reports to confirm the diagnoses and to document the extent of the disease in the 
gastrointestinal tract. Prevalent cases at recruitment and all cases of microscopic colitis 
were excluded. A nested case-control study design within the EPIC-IBD cohort was 
performed. Each case was matched with four randomly selected controls free of IBD and 
alive at the date of diagnosis of the case. The matching criteria were: age at enrolment (± 
6 months), gender, centre and enrolment date (± 3 months). There were 2 UC controls 
and 2 CD controls where the FFQ-data on alcohol consumption at baseline was missing 
which is why they were excluded from this study (table 1). 
Alcohol use was assessed as previously described27. At enrolment, alcohol 
consumption during the previous 12 months was recorded using validated country-
specific food frequency questionnaires (FFQs), and in a standardized lifestyle 
questionnaire, participants reported on their habitual consumption of alcoholic beverages 
per week when they were 20, 30, 40, or 50 years old. Glasses of alcoholic beverages 
reported in both questionnaires were converted into grams of alcohol per day (g/day) by 
applying empirically derived definitions of standard drinks for each beverage and country 
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of EPIC28. According to the amount of alcohol intake at enrolment, the participants 
(women and men, respectively) were classified into either: non-users, light user (>0-1 and 
>0-2 g/day; corresponding to 0.5 and 1 drink per week), below the recommended limits 
(BRL) user (>1-12 and >2-24 g/d; corresponding to 1 and 2 drinks per day), moderate user 
(>12-30 and >24-60 g/d; corresponding to 1-2 and 2-5 drinks per day) and heavy users 
(>30 and >60 g/d; corresponding to >2.5 and >5 drinks per day)29-31. According to the 
recall of consumption in the years previous to enrolment, average lifetime alcohol 
consumption was determined as a weighted average of intake at different ages, with 
weights equal to the time of individual exposure to alcohol at different ages; categories of 
alcohol use were then defined as described above. Never drinkers were those participants 
who did not report any consumption of alcoholic beverages at all points during their 
lifetime, while those who reported alcohol consumption at ages 20, 30, 40 or 50 years, 
but not during the 12 month prior to the recruitment were categorized as former users32. 
Finally, the lifetime pattern of alcohol use was assessed taking variation over time into 
account; alcohol consumers at enrolment were classified according to the highest level 
ever reached into ‘lifetime light’ (always being a light user), ‘lifetime BRL’ (all points in 
time using alcohol maximally BRL), ‘lifetime light to moderate’ (all points in time using 
alcohol maximally moderately), and ‘lifetime occasionally or always heavy’29-31. 
The self-completed questionnaires recorded: educational level and smoking status 
including the number of cigarettes. Information on dietary intake was derived from the 
FFQ, namely nine categories of consumption frequencies which varied from never to 
several times per day for approximately 200 food items. Using national databases of food 
composition from the EPIC-nutrient database, the 24-hours intake of total energy, food 
groups and individual nutrients were calculated33. 
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Conditional logistic regression was applied using SAS Enterprise 6.1 to calculate 
odds ratios (OR) and 95 percent confidence intervals (95% CI) for alcohol consumption at 
enrolment, during lifetime in average and for the lifetime pattern of alcohol use and the 
development of UC or CD. Light alcohol users (≤1 g/d and ≤2 g/d) were chosen as the 
reference group, as non-users may have heterogeneous reasons for abstention including 
health problems related to the diseases of interest and thus feigning a potential beneficial 
effect of alcohol use34, 35. 
Models were either unadjusted or adjusted for smoking status (never smoker, 
former smoker and smoker at enrolment), smoking duration, and educational attainment. 
Since the intake of polyunsaturated fatty acids were associated with UC in an earlier 
analysis36, sensitivity analyses were performed, additionally adjusting the models of UC 
and CD for decosahexaenoic (n-3 PUFA) and linoleic acid (n-6 PUFA) (g/d, continuously), 
as well as excluding cases diagnosed within 18 months after enrolment (to assess the 
possibility of reverse causation), and running the models separately for men and women.  
All analyses were performed using the statistical software SAS (Version 9.4, Enterprise 
Guide 6.1, SAS Institute Inc., Cary, NC, USA).  
Epidemiological data analyses of EPIC, including EPIC-IBD, may be conducted upon 
application addressed to the Steering Committee of EPIC. Each application will have to 
pass a review process by a scientific board. 
 
Results 
One hundred and ninety-eight UC and 84 CD incident cases and 792 matched UC-
controls and 336 matched CD-controls were included (Table 2). The median time from 
recruitment to IBD diagnosis was around 3.5 years (UC: 3.7, interquartile range 2.4-5.6; 
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CD 3.5, interquartile range 1.6-5.9 years). Participants who developed UC were on 
average 2 years older at the time of enrolment than those who developed CD. More 
women than men developed IBD (63% of UC cases and 81% of CD cases). The proportion 
of smokers at the time of enrolment, compared to their controls, was 32% and 24% 
(respectively) among CD cases, whilst for UC cases, the proportion of former smokers was 
40% compared to 32% of controls. Alcohol consumption was common, with only about 
7% of IBD cases and 9% of controls being non-users at recruitment. According to lifetime 
average use half of the IBD cases as well as the UC controls consumed less than about 7-
8g/d alcohol. The median and the range of average alcohol consumption during lifetime 
were lowest among CD controls. About 3% of the UC cases and controls, and about 5% 
and 7% of the CD cases and controls never used alcohol during lifetime. Most of the IBD 
cases and controls (about 77-83%) used alcohol during lifetime, although never heavily. 
Table 3 shows the ORs for UC and CD according to the three assessments of alcohol 
consumption used in this study. There were no associations for the development of UC or 
CD according to either: alcohol consumption at recruitment, lifetime average alcohol use 
or pattern of lifetime alcohol use compared to participants with light alcohol 
consumption. Odds ratios were similar when the models were either not adjusted or 
adjusted for smoking and education. Additional adjustment of the models for dietary fatty 
acids namely linoleic and decosahexaenoic acid, the exclusion of the cases diagnosed 
within the 18 months of follow-up and the separate calculation of the OR for women and 
men did not change the results.  
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Discussion 
This prospective study found there were no associations between alcohol consumption 
and the development of either UC or CD neither at recruitment, nor during lifetime from 
20 years of age onwards or for any lifetime patterns of alcohol use. The findings were 
similar for abstention from or cessation of alcohol use at some time point before 
recruitment.  
The literature previously discussed a role of the microbiota, genetics, diet and life style, 
and other environmental factors in the aetiology of IBD37-39. Alcohol use is part of socio-
cultural life and part of dietary patterns, and its consumption has been reported to be 
increasing over the last decades in many European populations40. Therefore, it was 
hypothesized that alcohol may influence inflammatory responses in the gastrointestinal 
tract as it can cause direct mucosal injury as well as increasing bacterial translocation8 and 
therefore increase the risk for IBD. Epidemiological studies on the role of alcohol in the 
aetiology of IBD are scarce18-20, 23-25, and consist of only retrospective case-control 
investigations, which studied 167 to 384 UC cases and 58 to 315 CD cases. These 
observational studies retrospectively collected information on alcohol consumption 
before the onset of symptoms for disease, and reported either: lower risk for regular 
alcohol users compared to little or non-users20, 23, no associations19, 24 or the associations 
disappeared when controlling for smoking, appendectomy or other confounders18, 25. Our 
study is the first to prospectively investigate alcohol consumption and the subsequent 
development of IBD, nested in EPIC, an European-wide cohort multi-centre study 
investigating diet and the development of cancer and other chronic diseases with over 
half a million participants in 10 countries. 
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The strength of our study is the prospective design of the data collection and the 
coverage of a large part of the European population to which the results are 
generalizable. The information on how alcohol was used during lifetime was recalled, but 
was collected before participants developed the symptoms of IBD or were diagnosed with 
the illness. Self-reported use of alcohol is prone to recall bias and social desirability bias41; 
nevertheless, the assessment of lifetime consumption at the time of recruitment in 
prospective studies was reliable in studies on weight development32 and mortality27. Due 
to the prospective recruitment, and the use of standardized FFQ and lifestyle 
questionnaires, we were able to adjust the models for variables that may be relevant for 
the development of IBD and also may be related to alcohol consumption (education, 
smoking, and polyunsaturated fatty acids). We used light alcohol users as reference 
because these participants in general tolerate alcohol; but its consumption is less likely to 
have any metabolic effect related to health. If the reference group were never-users, 
these may have several reasons for abstention including health problems related to the 
diseases of interest and thus feigning a potential beneficial effect of alcohol use42-44. A 
further strength of our study is that we included incident cases, which were medically 
verified, and that we performed a sensitivity analysis excluding those cases diagnosed 
early during the follow-up, to avoid including possible prevalent cases in the models. 
Our study has limitations. First is the relatively low number of cases of IBD compared to 
recently published numbers from a cohort in Europe45. The relatively small numbers of 
cases and the older age of our study population may limit our findings to IBD cases that 
occur later in life and are therefore not generalizable to the group of persons where the 
disease emerges at younger ages. However, the number of cases we identified was 
comparable to that of a previous cohort study (EC-IBD) which recruited new IBD cases in 
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1991-93, the same time the EPIC study recruited participants46, suggesting that our 
procedures of identification of cases were equivalent. Secondly, due to the demographic 
nature of the EPIC study, the number of cases diagnosed in young is low (the median age 
at diagnosis of our cases is more than 15 years older than that reported for Europe45). 
Nevertheless, it can be supposed that in early-age and young-age the genetic factors may 
play a more relevant role than environmental factors in the aetiology of IBD, and IBD in 
adulthood may be more influenced by the latter38. Therefore, the potential influence of 
alcohol use in IBD pathogenesis would be greater in an adult cohort, such as ours. Thirdly, 
the assessment of alcohol consumption was only performed at the enrolment of 
participants, and not surveyed prospectively. Therefore, it is not possible to know if 
participants changed their alcohol habits during follow-up and if this might have any 
influence in the risk of IBD. However, as half of the cases were diagnosed during the first 
3.5 years of follow-up, it is conceivable that factors reported at recruitment are still 
related to disease development. Alcohol consumption was reported to be increasing over 
the last decades in many European populations40, together with an increase in the 
incidence of IBD45, although our results would suggest the two are not associated.  
In conclusion, our data does not support a role for alcohol consumption in the 
aetiology of either UC or CD.  
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Table 1. Characteristics of the EPIC-cohorts and case ascertainment in the EPIC-IBD nested case-control study 
Country 
(centre) 
Size of 
cohort 
No. 
Years of 
recruitment 
Month and 
year of last 
diagnosis in 
the data set 
Nature of cohort Number of participants  
with incident IBD 
a) Total 
b) Within the 1st 5 years 
  UC 
cases/controls 
CD 
cases/controls 
Denmark 
(Aarhus, 
Copenhagen) 
57,053 1993-97 11/2001 Population-based cohort of men and women 
aged 50–64 years. Cases identified from 
national registry of inflammatory bowel 
disease. 
a) 49 / 196 
b) 40 / 160 
16 / 64 
13 / 52 
United 
Kingdom 
(Norfolk) 
25,639 1993-97 12/2002 Population-based cohort of men and women 
aged 45–74 years. Cases identified from 
follow-up questionnaires, in-patient 
admission data and histopathology records. 
a) 51 / 206 
b) 42 / 170 
16 / 66 
13 / 55 
Germany 
(Heidelberg) 
25,540 1994-98 11/2003 Population-based cohort of men aged 45–65 
years and women aged 35–65 years. Cases 
identified from follow-up questionnaires and 
subsequently were medically verified. 
a) 6 / 24 
b) 6 / 24 
11 / 44 
5 / 20 
Germany 
(Potsdam) 
27,548 1994-98 09/2006 Population-based cohort of men and women, 
aged 35–64 years. Cases identified from 
follow-up questionnaires and subsequently 
were medically verified. 
a) 37 / 148 
b) 19 / 76 
5 / 20 
3 / 12 
The 
Netherlands 
(Amsterdam, 
Doetinchem, 
Maastricht, 
Utrecht) 
40,092 1993-97 01/2008 Population based cohort of men and women, 
aged 20-70 years in 3 cities (Amsterdam, 
Doetinchem & Maastricht) and women from 
the breast cancer screening programme in 
Utrecht. Cases were identified using a 
population-based pathology database with 
subsequent verification via hospital records 
a) 13 / 52 
b) 5 / 20 
7 / 27 
3 / 11 
France 72,996 1993-97 06/2005 Women aged 40–65 years, enrolled in the 
Nation-wide health insurance programme 
(MGEN) for teachers and school workers. 
Cases identified via insurance records. 
a) 33 / 130 
b) 16 / 53 
25 / 99 
15 / 59 
Italy (Florence) 13,583 1993-97 05/2002 Population-based cohort of men aged 45-64 
and women aged 35.64 years. Cases 
identified from regional registry of 
inflammatory bowel disease 
a) 9 / 36 
b) 8 / 32 
4 / 16 
3 / 12 
UC ulcerative colitis, CD Crohn’s disease  
Table 2. Characteristics of participants  
 UC Cases  
(n=198) 
UC Controls 
(n=792) 
CD Cases 
(n=84) 
CD Controls 
(n=336) 
Age at recruitment (years, median (range) 52.7 (23.2, 77.1) 52.8 (23.2, 77.1) 50.9 (23.0, 75.8) 50.8 (22.8, 76.2) 
Gender (women (n, %))  124 (62.6) 497 (62.8) 68 (81.0) 269 (80.1) 
Age at diagnosis (years, median (range) 56.9 (28.0, 80.8) – 55.8 (27.0, 78.7) – 
Time between recruitment and diagnosis  
(years, median (min, max)) 
IQR 
 
3.7 (0.0, 12.5) 
(2.4, 5.6) 
 
 
– 
 
3.5 (0.1, 11.9) 
(1.6, 5.9) 
 
 
– 
Current smoker (%) 
Former smoker (%) 
23.4 
40.1 
21.9 
32.1 
32.1 
26.2 
23.8 
29.5 
Intakes: 
Energy (kcal/d, mean (SD)) 
 
2198 (664) 
 
2131 (653) 
 
2105 (549) 
 
2054 (594) 
decosahexaenoic acid (g/d, mean (SD)) 0.26 (0.20) 0.28 (0.24) 0.25 (0.22) 0.27 (0.27) 
linoleic acid (g/d; mean (SD)) 12.2 (5.1) 11.1 (5.2) 9.5 (3.7) 11.0 (5.4) 
University degree (%) 28.3 29.2 29.8 30.1 
Alcohol use at recruitment 
% non-user 
Median g/d (min, max) 
 
7.6 
9.1 (0.0, 155.9) 
 
8.8 
8.9 (0.0, 184.1) 
 
7.1 
6.4 (0.0, 72.2) 
 
8.9 
7.1 (0.0, 114.9) 
Lifetime average alcohol use 
Median g/d (min, max) 
 
7.8 (0.0, 114.6) 
 
7.9 (0.0, 228.0) 
 
6.8 (0.0, 134.6) 
 
5.5 (0.0, 65.6) 
Lifetime pattern of alcohol use (%) 
Never 
Former1 
Lifetime light2 
Lifetime BRL3 
Lifetime light to moderate4 
Lifetime occasionally or always heavy5 
 
3.0 
4.6 
14.1 
33.3 
29.8 
15.2 
 
3.4 
5.4 
13.0 
33.8 
30.3 
14.0 
 
4.8 
2.4 
13.1 
40.5 
29.8 
9.5 
 
6.9 
2.1 
14.9 
35.7 
29.2 
11.3 
IQR: interquartile range; BRL: below the recommended limits. 
1Those participants reported the use of alcohol at ages: 20, 30, 40, or 50 years of age but not for the time of enrolment. 
2Always being a light user (>0 g/d–1 or 2 g/d for women or men). 
3At least one point time being BRL user (>1 or 2 g/d–12 or 24 g/d for women or men). 
4At least one point time being moderate user (>12 or 24 g/d–30 or 60 g/d for women or men). 
5At least one point time being heavy user (>30 or 60 g/ for women or men). 
  
 
Table 3. Odds ratios for use of alcohol and the development of IBD  
Alcohol use Cases  
n 
Controls 
n 
OR1  
(95% CI)1 
OR2  
(95% CI)2 
Ulcerative Colitis     
Alcohol use at recruitment 
Non-use 
Light3 
BRL4 
Moderate5 
Heavy6 
 
15 
54 
63 
45 
21 
 
70 
200 
278 
169 
75 
 
0.77 (0.40-1.49) 
REF 
0.84 (0.56-1.28) 
0.99 (0.62-1.58) 
1.04 (0.57-1.89) 
 
0.80 (0. 41-1. 59) 
REF 
0.82 (0.54-1.25) 
0.95 (0.58-1.54) 
0.95 (0.52-1.76) 
Lifetime average alcohol use 
Never user 
Former user7 
Light3 
BLR4 
Moderate5 
Heavy6 
 
6 
9 
45 
88 
38 
12 
 
27 
43 
174 
351 
168 
29 
 
0.88 (0.36-2.19) 
0.78 (0.35-1.74) 
REF 
1.03 (0.68-1.56) 
0.91 (0.60-1.39) 
1.67 (0.81-3.45) 
 
1.10 (0.43-2.80) 
0.79 (0.34-1.81) 
REF 
1.14 (0.74-1.74) 
0.85 (0.55-1.32) 
1.70 (0.80-3.58) 
Pattern of lifetime alcohol use 
Never 
Former 
Lifetime light8 
Lifetime BLR9 
Lifetime light to moderate10 
Lifetime occasionally or always heavy11 
 
6 
9 
28 
66 
59 
30 
 
27 
43 
103 
268 
240 
111 
 
0.80 (0.30-2.12) 
0.72 (0.30-1.73) 
REF 
0.90 (0.54-1.51) 
0.90 (0.53-1.53) 
0.99 (0.54-1.82) 
 
0.92 (0.34-2.48) 
0.67 (0.27-1.66) 
REF 
0.86 (0.51-1.47) 
0.82 (0.48-1.42) 
0.86 (0.46-1.64) 
 
Table continuing 
  
Table continuing 
Alcohol use 
Cases 
n 
Controls 
n 
OR1  
(95% CI)1 
OR2  
(95% CI)2 
Crohn’s Disease     
Alcohol use at recruitment 
Non-use 
Light3 
BLR4 
Moderate5 
Heavy6 
 
6 
24 
34 
16 
4 
 
30 
86 
115 
78 
27 
 
0.70 (0.26-1.93) 
REF 
1.05 (0.57-1.92) 
0.73 (0.36-1.46) 
0.52 (0.17-1.64) 
 
0.71 (0.25-2.08) 
REF 
1.00 (0.52-1.95) 
0.67 (0.30-1.49) 
0.43 (0.13-1.47) 
Lifetime average alcohol use 
Never user 
Former user7 
Light3 
BLR4 
Moderate5 
Heavy6 
 
4 
2 
21 
37 
19 
1 
 
23 
7 
86 
146 
67 
7 
 
0.64 (0.20-2.06) 
1.33 (0.25-7.08) 
REF 
0.97 (0.53-1.80) 
1.16 (0.61-2.21) 
0.58 (0.07-4.71) 
 
0.64 (0.19-2.19) 
1.28 (0.21-7.79) 
REF 
0.97 (0.50-1.89) 
0.88 (0.43-1.81) 
0.57 (0.06-5.20) 
Pattern of lifetime alcohol use 
Never 
Former7 
Lifetime light8 
Lifetime BLR9 
Lifetime light to moderate10 
Lifetime occasionally or always heavy11 
 
4 
2 
11 
34 
25 
8 
 
23 
7 
50 
120 
98 
38 
 
0.73 (0.21-2.56) 
1.52 (0.26-8.93) 
REF 
1.30 (0.62-2.70) 
1.15 (0.52-2.50) 
0.98 (0.36-2.68) 
 
0.71 (0.19-2.67) 
1.48 (0.22-9.99) 
REF 
1.26 (0.58-2.74) 
1.00 (0.42-2.39) 
0.82 (0.28-2.42) 
BRL: Below the recommended limits. 
1Not adjusted. 
2Adjusted for educational attainment and smoking status. 
3>0 g/d–1 or 2 g/d for women or men. 
4>1 or 2 g/d–12 or 24 g/d for women or men. 
5>12 or 24 g/d–30 or 60 g/d for women or men. 
6>30 or 60 g/ for women or men. 
7Those participants reported the use of alcohol at ages: 20, 30, 40, or 50 years of age but not for the time of enrolment. 
8Always being a light user. 
9At least one point time being BRL user. 
10At least one point time being moderate user. 
11At least one point time being heavy user. 
